The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial of very low to low-dose continuous azacitidine in combination with standard doses of lenalidomide and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.
 
Frederic J. Reu
Research Funding - Celgene; Novartis; Takeda
 
Dale Grabowski
No Relationships to Disclose
 
Reda Z. Mahfouz
No Relationships to Disclose
 
Hillard M. Lazarus
No Relationships to Disclose
 
Robert M. Dean
No Relationships to Disclose
 
Beth Faiman
Consulting or Advisory Role - Celgene; Millennium; Onyx
 
Janice Reed
No Relationships to Disclose
 
Mary Ann Karam
No Relationships to Disclose
 
Kimberly Hamilton
No Relationships to Disclose
 
Sherry Fada
No Relationships to Disclose
 
Matt E. Kalaycio
No Relationships to Disclose
 
Jason Neil Valent
Speakers' Bureau - Celgene; Millennium
 
Christy Joy Samaras
No Relationships to Disclose
 
Ronald M. Sobecks
No Relationships to Disclose
 
Linda McCowen
No Relationships to Disclose
 
Jamie Elberson
No Relationships to Disclose
 
Hien Liu
No Relationships to Disclose
 
Yogen Saunthararajah
No Relationships to Disclose
 
Yap Chew
Employment - Zymo Research
 
Mitchell R. Smith
Honoraria - Spectrum Pharmaceuticals
Consulting or Advisory Role - Celgene
Research Funding - Gilead Sciences (Inst); Millennium (Inst); Seagen (Inst)